Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.03 and traded as high as $2.98. Spero Therapeutics shares last traded at $2.94, with a volume of 1,836,464 shares traded.

Spero Therapeutics Price Performance

The company has a market cap of $164.38 million, a price-to-earnings ratio of -2.30 and a beta of 1.31. The stock has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.03.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. The company had revenue of $5.87 million for the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. Sell-side analysts expect that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in Spero Therapeutics in the 4th quarter valued at approximately $31,000. Three Seasons Wealth LLC acquired a new stake in Spero Therapeutics in the 4th quarter valued at approximately $31,000. Virtu Financial LLC acquired a new stake in Spero Therapeutics in the 4th quarter valued at approximately $47,000. Prudential Financial Inc. acquired a new stake in Spero Therapeutics in the 4th quarter valued at approximately $51,000. Finally, Jane Street Group LLC acquired a new stake in Spero Therapeutics in the 4th quarter valued at approximately $54,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.